Cargando…
Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights
Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity can result from cells displaying distinct mTF-regulat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133465/ https://www.ncbi.nlm.nih.gov/pubmed/35584622 http://dx.doi.org/10.1016/j.xcrm.2022.100632 |
_version_ | 1784713574638157824 |
---|---|
author | Shendy, Noha A.M. Zimmerman, Mark W. Abraham, Brian J. Durbin, Adam D. |
author_facet | Shendy, Noha A.M. Zimmerman, Mark W. Abraham, Brian J. Durbin, Adam D. |
author_sort | Shendy, Noha A.M. |
collection | PubMed |
description | Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity can result from cells displaying distinct mTF-regulated cell states, which co-exist within the tumor. One archetypal tumor associated with transcriptionally regulated heterogeneity is high-risk neuroblastoma (NB). Patients with NB have poor overall survival despite intensive therapies, and relapsed patients are commonly refractory to treatment. The cellular populations that comprise NB are marked by different cohorts of mTFs and differential sensitivity to conventional therapies. Recent studies have highlighted mechanisms by which NB cells dynamically shift the cell state with treatment, revealing new opportunities to control the cellular response to treatment by manipulating cell-state-defining transcriptional programs. Here, we review recent advances in understanding transcriptionally defined cancer heterogeneity. We offer challenges to the field to encourage translation of basic science into clinical benefit. |
format | Online Article Text |
id | pubmed-9133465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91334652022-05-27 Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights Shendy, Noha A.M. Zimmerman, Mark W. Abraham, Brian J. Durbin, Adam D. Cell Rep Med Review Cell state is controlled by master transcription factors (mTFs) that determine the cellular gene expression program. Cancer cells acquire dysregulated gene expression programs by mutational and non-mutational processes. Intratumoral heterogeneity can result from cells displaying distinct mTF-regulated cell states, which co-exist within the tumor. One archetypal tumor associated with transcriptionally regulated heterogeneity is high-risk neuroblastoma (NB). Patients with NB have poor overall survival despite intensive therapies, and relapsed patients are commonly refractory to treatment. The cellular populations that comprise NB are marked by different cohorts of mTFs and differential sensitivity to conventional therapies. Recent studies have highlighted mechanisms by which NB cells dynamically shift the cell state with treatment, revealing new opportunities to control the cellular response to treatment by manipulating cell-state-defining transcriptional programs. Here, we review recent advances in understanding transcriptionally defined cancer heterogeneity. We offer challenges to the field to encourage translation of basic science into clinical benefit. Elsevier 2022-05-17 /pmc/articles/PMC9133465/ /pubmed/35584622 http://dx.doi.org/10.1016/j.xcrm.2022.100632 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Shendy, Noha A.M. Zimmerman, Mark W. Abraham, Brian J. Durbin, Adam D. Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights |
title | Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights |
title_full | Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights |
title_fullStr | Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights |
title_full_unstemmed | Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights |
title_short | Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights |
title_sort | intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133465/ https://www.ncbi.nlm.nih.gov/pubmed/35584622 http://dx.doi.org/10.1016/j.xcrm.2022.100632 |
work_keys_str_mv | AT shendynohaam intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights AT zimmermanmarkw intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights AT abrahambrianj intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights AT durbinadamd intrinsictranscriptionalheterogeneityinneuroblastomaguidesmechanisticandtherapeuticinsights |